Table II.

Phenotypic measurements in the HAPI Heart Study

Category	Measurements
Demographics	Age, sex, marital status, parity, occupation
Medical history	Hypertension, diabetes, cancer, myocardial infarction, stroke, heart or carotid surgery, medication use
Lifestyle	Smoking, physical activity
Anthropometry and resting BP and HR	Height, weight, waist circumference, blood pressure (BP) and heart rate (HR) (three measures)
Baseline blood analyses	Complete blood count (CBC), fasting serum glucose, insulin, adiponectin, AST, ALT, TSH, BUN, creatinine, lipid profile and subfractions, lipid particle size, measures of inflammation
Baseline urine analyses	Sodium, creatinine
Other	Carotid intima media thickness (IMT), pulse wave velocity (PWV), ankle-brachial index (ABI), echocardiogram
Intervention-specific:
High fat challenge	Lipids: fasting blood sample (just prior to the test) and at 1, 2, 3, 4, and 6 hours after the test
	Brachial artery flow-mediated vasodilation (FMD): fasting and at 2, 4, and 6 hours after the test
Cold pressor stress test	BP: stable baseline and during and after the test at 1, 2, 3, 4, 5, 7.5, 10, 15, and 20 minutes
	HR: along with BP measurements
	Brachial artery reactivity (BART): before and during the test and after withdrawal from ice water
High/low salt diets	Ambulatory BP and HR monitoring: on the 6th day of each diet for 24 hours
	Urine sodium and creatinine: first morning void collected on days 4, 5, and 6 of each diet
Aspirin	Platelet aggregation and platelet function assays: whole blood samples before and after 14 days of aspirin therapy using collagen, ADP and arachidonic acid as agonists
	Urinary 11-dehydrothromboxane B2 (TXB2): first morning void before and after 14 days of aspirin therapy